Evaluation of predictors of erectile dysfunction and hypogonadism in men with types 2 diabetes mellitus
DOI:
https://doi.org/10.18203/2349-3933.ijam20205038Keywords:
Erectile dysfunction, Hypogonadism, Sex hormone binding globulin, Types 2 diabetesAbstract
Background: Now a day erectile dysfunction (ED) and hypogonadism of the patients with type 2 diabetes mellitus (T2DM) become two common complaints. The association among hypogonadism, erectile dysfunction and type 2 diabetes of man seem to be increased. The aim of this study was to evaluate the predictors of erectile dysfunction and hypogonadism in men with types 2 diabetes mellitus (T2DM).
Methods: This was a cross-sectional study which was conducted in the Department of Shaheed Monsur Ali Medical College Hospital, Dhaka, Bangladesh Hospital, Bangladesh during the period from January 2019 to December 2019. In total 352 newly detected T2DM male patients, with complete data were finalized as the study population. All data were processed by using SPSS program version 23.0.
Results: In this study, according to complement fixation test (cFT) and androgen deficiency in the aging male (ADAM) criteria, 119 (33.81%) participant had low cFT& ADAM positive under hypogonadal, 84 (23.86%) were with normal TT & ADAM negative (eugonadal), 37 (10.51%) were with low TT & ADAM negative (eugonadal), 112 (31.82%) were with normal TT & ADAM positive (eugonadal). On the other hand, according to the cFT and ADAM score in total 119 (33.81%) hypogonadal patients were with low cFT & ADAM positive. Besides this, 102 (43.78%) eugonadal patients were with normal cFT & ADAM negative and 131 (56.22%) eugonadal patients were with normal cFT & ADAM positive.
Conclusions: Hence, universal screening of testosterone level and androgen deficiency symptoms is recommended in newly detected T2DM patients.
References
Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 444:840.
International Diabetes Federation. IDF Diabetes Atlas. Epidemiology and Morbidity. International Diabetes Federation. Available at: http://www.idf.org/. Accessed on 01 March 2020.
Hackett GI. Erectile dysfunction, diabetes and cardiovascular risk. Brit J Diabet. 2016;16(2):52-7.
Abdelraouf M, Sonbol K. Study of risk factors for erectile dysfunction in patients with type 2 diabetes mellitus: Correlation to serum testosterone level. Alexand J Medic. 2018;54:319-21.
Hackett GI. Erectile dysfunction, diabetes and cardiovascular risk. Brit J Diabet. 2016;16(2):52-7.
Basaria S. Male hypogonadism. Lancet. 2014;383(9924):1250-63.
Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010;64:682-96.
Aydogan U, Aydogdu A, Akbulut H, Sonmez A, Yuksel S, Basaran Y, et al. Evaluation of the isokinetic muscle strength, balance and anaerobic performance in patients with young male hypogonadism. Endoc J. 2012;59(4):3217.
Aydogan U, Aydogdu A, Akbulut H, Sonmez A, Yuksel S, Basaran Y, et al. Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropichypogonadal males and impacts of testosterone replacement therapy on these conditions. Endocr J. 2012;59(12):1099-105.
Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormonebinding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006;91:843-50.
Sorisky A. Late-onset hypogonadism in middle-aged and elderly men. N Engl J Medic. 2010;363(19):1867-8.
Akter S, Rahman M, Abe S, Sultana P. Prevalence of diabetes and prediabetes and their risk factors among Bangladeshi adults: a nationwide survey. Bullet W Heal Organiz. 2014;92:204-13.
Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko S, Tishova Y, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18:5-15.
Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos E, Flier JS. Nature. 1996;382:250-2.
Schneider JE, Wade GN. Availability of metabolic fuels controls estrous cyclicity of Syrian hamsters. Science. 1989;244:1326-8.
Maejima Y, Kohno D, Iwasaki Y, Yada T. Insulin suppresses ghrelin-induced calcium signaling in neuropeptide Y neurons of the hypothalamic arcuate nucleus. Aging. 2011;310:92-7.
Trinick TR, Feneley MR, Welford H, Carruthers M. International web survey shows high prevalence of symptomatic testosterone deficiency in men. Aging Male. 2011;14:10-5.
Seftel AD. Male hypogonadism. Part I: Epidemiology of hypogonadism. Int J Impot Res. 2006;18:115-20.
Hu FB. Globalization of Diabetes. Diabet Car. 2011;34:1249-57.
